Massachusetts Financial Services Co. MA reduced its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 0.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 724,187 shares of the company's stock after selling 5,643 shares during the period. Massachusetts Financial Services Co. MA owned 1.47% of Prestige Consumer Healthcare worth $56,552,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Kestra Investment Management LLC acquired a new position in Prestige Consumer Healthcare in the 4th quarter valued at $27,000. CIBC Private Wealth Group LLC grew its holdings in shares of Prestige Consumer Healthcare by 48.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after purchasing an additional 152 shares during the period. Headlands Technologies LLC acquired a new position in Prestige Consumer Healthcare during the fourth quarter valued at approximately $40,000. GAMMA Investing LLC raised its stake in shares of Prestige Consumer Healthcare by 18.9% in the 4th quarter. GAMMA Investing LLC now owns 1,383 shares of the company's stock valued at $108,000 after acquiring an additional 220 shares during the period. Finally, Blue Trust Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 24.8% during the 4th quarter. Blue Trust Inc. now owns 2,190 shares of the company's stock valued at $158,000 after acquiring an additional 435 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.
Prestige Consumer Healthcare Trading Down 4.8 %
PBH traded down $4.00 during trading on Thursday, reaching $79.19. The company had a trading volume of 124,588 shares, compared to its average volume of 281,146. The firm's 50-day simple moving average is $84.33 and its 200 day simple moving average is $79.69. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $90.04. The company has a market cap of $3.92 billion, a price-to-earnings ratio of 18.54, a PEG ratio of 2.69 and a beta of 0.47.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.
Insider Buying and Selling at Prestige Consumer Healthcare
In other news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction on Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the sale, the senior vice president now directly owns 17,157 shares of the company's stock, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.60% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have weighed in on PBH. StockNews.com cut Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Tuesday. Canaccord Genuity Group raised their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a report on Friday, February 7th. Royal Bank of Canada boosted their price objective on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a "sector perform" rating in a report on Friday, March 21st. Raymond James upgraded Prestige Consumer Healthcare to a "moderate buy" rating in a research note on Thursday, December 19th. Finally, Oppenheimer boosted their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $93.33.
Check Out Our Latest Stock Report on Prestige Consumer Healthcare
About Prestige Consumer Healthcare
(
Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
See Also
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
